Navigating Clinical Trials: Essential Knowledge for Dermatologists-Practical Points in Vitiligo Studies

Video Transcription

Video Summary

In this talk, Dr. John Harris from the University of Massachusetts Chan Medical School discusses practical aspects and exciting results of vitiligo clinical studies. Vitiligo is a common skin condition affecting 1.4% of the population, often appearing before age 20 and associated with conditions like type 1 diabetes and Hashimoto's thyroiditis. Various presentations, such as segmental and active vitiligo, impact patient participation in clinical trials. The first study reviewed is a phase three trial using topical ruxolitinib, showing significant improvement in vitiligo lesions over two years. Another trial with oral ritlecitinib demonstrated the challenge of treating active disease, while upadacitinib trials highlighted differing patient responses based on disease stability. Key considerations when conducting trials include treatment duration, lesion characteristics like poliosis, and the use of Woods LAMP for better visibility of the condition, especially with fair-skinned individuals. These factors influence trial design and the meaningful interpretation of results.

Asset Subtitle

by John Harris, MD, PhD, FAAD

Keywords

vitiligo

clinical trials

ruxolitinib

ritlecitinib

Woods LAMP